For example, UCART19, an allogeneic CD19-targeting CAR-T therapy with TRAC knockout via TALENs, showed a low GvHD incidence (10% grade 1 acute skin GvHD) in both pediatric and adult B-ALL patients (NCT02808442, NCT02746952) [66]. Here, CD19 is linked to graft versus host disease.